Skip to main content
Clinical Trials/NL-OMON25255
NL-OMON25255
Other
Not Applicable

A randomized, placebo-controlled, double blind trial to study the effects of vitamin K2 and arterial calcification in patients with type 2 diabetes

MC Utrecht0 sites0 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vitamin K, menaquinone-7, arterial calcification, dp-ucMGP, diabetes patiënts, arterial stiffness, bone metabolism.
Sponsor
MC Utrecht
Status
Other
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
MC Utrecht

Eligibility Criteria

Inclusion Criteria

  • Middle aged men and women ¡Ý 40 years.
  • \- Diagnosed with type 2 diabetes.

Exclusion Criteria

  • \- Contra\-indication for undergoing 18F\-NaF PET/CT scan (pregnancy, breastfeeding, recent radiotherapy or chemotherapy).
  • \- Subject underwent amputation.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
A randomized, placebo-controlled, double blind trial to study the effects of Etidronate on ectopic CALCIfication in FAhr*s Disease or syndrome.Fahr's diseaseprimary familial brain calcification10007963
NL-OMON53560niversitair Medisch Centrum Utrecht98
Completed
Phase 2
A randomized, placebo-controlled, double blind trial to investigate whether vitamin K2 can influence ongoing calcium deposition in patients with type 2 diabetesArterial calcificationcardiovascular disease10003216
NL-OMON45148niversitair Medisch Centrum Utrecht70
Active, not recruiting
Phase 1
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2020-000082-16-PLEsoCap AG42
Active, not recruiting
Phase 4
Can treatment with Cerebrolysin improve recovery after acute ischemic stroke?Radiologically confirmed acute ischemic stroke with onset within 72 hours prior to screeningCirculatory SystemAcute ischemic stroke
ISRCTN88122184The foundation for the study of neuroscience and neuroregeneration290
Active, not recruiting
Phase 1
A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusActive eosinophilic esophagitisMedDRA version: 20.1Level: PTClassification code 10064212Term: Eosinophilic oesophagitisSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2020-000082-16-NLEsoCap AG42